U.S. · HEALTH · NOV 10, 3:18 PM ET
Makers of GLP-1 drugs ordered to add warnings about rare eye condition that can lead to blindness
Reported by 32 outlets in the past day, including BBC, The Guardian, Ars Technica.
1What happened
The US Food and Drug Administration says Ozempic, Wegovy, and other weight-loss drugs must have labels about the condition, known as NAION. BBC ↗
2Also reported
The risk appears small and data is mixed, but FDA wants patients to be aware. Ars Technica ↗
Sources
- Makers of GLP-1 drugs ordered to add warnings about rare eye condition that can lead to blindness ↗BBC
- FDA warns of rare eye condition causing blindness from GLP-1 weight loss medications ↗The Guardian
- FDA warns GLP-1 drugs may pose risk of rare condition that causes vision loss ↗Ars Technica
- FDA warns of vision loss risk linked to popular GLP-1 drugs like Wegovy, Zepbound ↗CNBC
- FDA orders new warning labels on Ozempic, Wegovy over rare risk of permanent vision loss ↗Fox Business
- FDA warns of rare vision-loss side effect from GLP-1 drugs ↗CBS News